Should the Lung Ultrasound Score Be Used to Evaluate Interstitial Syndrome Severity in Intensive Care Units? A Prospective Observational Study

Eléonore Vasseur, MD1*; Florence Dupriez, MD PHD1,2; Caroline Poletti, MD1; Zoi Papadoyannaki, MD1; Aurélien Ledoux, MD3; Romain Courcelle, MD3; Marco Vinetti, MD4; Jean-Baptiste Mesland, MD5; Gauthier Nendumba, MD6; Paul Geukens, MD3

(1) Emergency Department, Clinique Universitaire Saint Luc, Bruxelles, Belgium

(2) Université Catholique de Louvain (UCLouvain), Bruxelles, Belgium 

(3) Intensive Care Unit, CHU Helora, Hôpital de Jolimont, Haine-Saint-Paul, Belgium

(4) Intensive Care Unit, Clinique Saint Pierre, Ottignies, Belgium

(5) Intensive Care Unit, Clinique Universitaire Saint Luc, Bruxelles, Belgium

(6) Intensive Care Unit, Centre Hospitalier Universitaire UCL Namur, Yvoir, Belgium

*Corresponding Author: Dr. Eléonore Vasseur (email: e.vasseur@europehospitals.be)


Download article PDF – POCUS Journal 2026;11(2):111-120

DOI: https://doi.org/10.24908/pocusj.v11i02.20270


Abstract

Background: The correlation between the lung ultrasound score (LUSS), a quantitative point of care ultrasound (POCUS) method used to evaluate pulmonary interstitial syndrome (IS), and the arterial oxygen pressure-to-fraction of inspired oxygen (P/F) ratio, a severity marker for IS, has been demonstrated in small cohorts of COVID-19 patients, supporting the utility of LUSS as a reliable severity indicator for IS. This post-pandemic study investigated the same correlation in a larger cohort of intensive care unit (ICU) patients with IS of any etiology, potentially supporting the broader application of the LUSS as a severity indicator across all types of IS. Methods: This was a prospective multicentre observational study. A sample of adult patients who were admitted to the ICU with acute respiratory failure (ARF) and required arterial blood gas analysis (ABG) was used. The primary endpoint was to assess whether the correlation between the LUSS and P/F ratio in ICU patients with IS reached a prespecified magnitude (r = −0.70), defined a priori based on previous findings for sample size estimation. Results: In total, 86 patients were included. The results showed a weak negative linear correlation between LUSS and P/F ratio with a correlation of r = -0.2945 (95% CI: -0.4767 to -0.0881). Conclusion: In this heterogeneous ICU cohort, LUSS showed a weak correlation with P/F ratio. This suggests that although LUSS is a useful tool for assessing disease severity in COVID-19 pneumonia, it may not be appropriate as a standalone severity marker of IS.

Introduction

Due to the presence of multiple artefacts caused by air-water interfaces, lung ultrasound has previously been considered a poor diagnostic tool for lung pathologies. However, lung point of care ultrasound (POCUS) has been developed for use with critically ill patients. This method leverages these artefacts to define ultrasonographic profiles that correspond to different lung conditions [1,2].

Interstitial syndrome (IS) refers to the lung ultrasound pattern characterized by diffuse B-lines [3]. This pattern may be observed in a variety of acute and chronic conditions, including viral or bacterial pneumonia, cardiogenic pulmonary edema, acute respiratory distress syndrome (ARDS), and chronic interstitial lung diseases (CILD). Although chronic obstructive pulmonary disease (COPD) is not classified as an interstitial lung disease, B-lines can be observed in these patients, reflecting chronic interstitial changes[4]. The lung ultrasound score (LUSS) is a lung POCUS method that is based on the quantification of B-lines and developed as a quantitative method to assess lung aeration[5]. LUSS has been associated with mortality in ARDS as well as severity and mortality in COVID-19 pneumonia [6,7]. 

The arterial oxygen pressure-to-fraction of inspired oxygen (P/F) ratio obtained by arterial blood gas analysis (ABG) reflects hypoxemia and indicates severity in ARDS [8]. A negative linear correlation between LUSS and P/F ratio has been identified in cohorts of patients admitted to intensive care units (ICU) with COVID-19 pneumonia, ARDS,or cardiogenic shock [7,9–11]. This finding reinforces the hypothesis that LUSS could reflect IS severity. As the precise etiology of IS is often initially unknown, the O2LUSS study was designed to assess the correlation between LUSS and P/F ratio in a large group of patients presenting to the emergency department with all types of IS [12]. A moderate negative correlation was shown in 162 patients,suggesting that LUSS could be generalized as a severity assessment tool.

This study aimed to determine the strength of the correlation between LUSS and P/F ratio in ICU patients, as compared to the correlation previously observed in the emergency department in the O2LUSS study [12]. Additionally, this study evaluated the  correlation between the LUSS and P/F ratio at both 24 and 48 hours and assessed the correlation between the LUSS and the sequential organ failure assessment (SOFA) score. The study also explored the influence of the SOFA score, determined pleural effusion and size, and conducted subgroup analyses to understand the potential of the LUSS as a severity assessment tool.

Methods

Design and settings

This prospective, multicentric, observational study was conducted in three Belgian hospitals: one tertiary centre (Clinique Universitaire Saint Luc, CUSL) and two secondary centres (Hôpital de Jolimont and Clinique Saint Pierre Ottignies). Patients were recruited between February 1, 2023, and August 31, 2024.

Patients were eligible for this study if they were admitted to the ICU with signs and symptoms of acute respiratory failure (ARF), and if the treating ICU physician indicated ABG, according to their clinical judgment and standard practice. The investigator then identified patients who were over 17 years of age and who provided signed consent (or from their legal representative or through plausible delayed consent). Patients were not included if they had COPD, active asthma, CILD or severe trauma, required veno-venous or veno-arterial extracorporeal membrane oxygenation, were in the first 24 hours post-operatively, or if lung POCUS was impossible due to anatomical reasons. Inclusion and exclusion criteria are listed in Table 1. If patients met the inclusion criteria, an independent investigator performed lung POCUS to calculate the LUSS. The presence and size of pleural effusion were also documented. Lung POCUS was performed at the patient’s bedside within 10 minutes of arterial blood gas sampling to minimize variations in patient condition and respiratory support between measurements. The oxygen delivery mode was recorded at the time of ABG. For patients receiving oxygen via a nasal cannula, simple oxygen mask, or non-rebreathing mask, FiO2 was estimated by the investigator from the oxygen flow rate in litres per minute (L/min) using a standardized conversion table (Table 2). FiO2 was recorded directly from device settings for patients who were receiving oxygen through high flow canula (HFNC), non-invasive ventilation (NIV) or invasive ventilation (IV). The etiology of ARF was collected from patient medical records, and the final diagnosis was assigned by the treating ICU team. More than one etiology was allowed. No independent review or formal adjudication were performed. Patients with a LUSS of <2 or for whom delayed consent was not obtained were secondarily excluded. Follow-up LUSS at 24 hours and 48 hours was performed when feasible. This was dependent on the availability of an investigator and whether the patient remained in the ICU and continued to meet all inclusion criteria. Patient-level reasons for missed follow-up were not systematically recorded. Mortality and ventilation-free days at 28 days were collected.

Table 1. Inclusion and exclusion criteria.
Inclusion criteria
Acute respiratory failure (ARF)
Indication for arterial blood gas analysis (ABG)
Age > 17 years
Signed consent or delayed consent plausible
Exclusion criteria
Chronic obstructive pulmonary disease (COPD)
Active asthma
Chronic interstitial lung disease (CILD)
Veno-venous or veno-arterial extracorporeal membrane oxygenation
Severe trauma
<24 hours post-operative
Lung point of care ultrasound (POCUS) non-feasible
Table 2. Fraction of inspired oxygen (FiO2) according to oxygen supplementation device.
Nasal cannulaSimple maskNon-rebreathing mask
1L24%
2L28%
3L32%
4L36%
5L40%40%
6L44%44%
7L48%
8L52%60%
9L56%70%
10L60%75%
12L85%
15L90%

The primary endpoint was to evaluate, in ICU patients with IS, whether the correlation between LUSS and the P/F ratio reached a prespecified magnitude (target r = −0.70). The target correlation was defined a priori based on previous findings and was used for sample size planning; there was no formal statistical comparison with the prior cohort. Secondary outcomes included evaluating the correlation between the LUSS and the SOFA score, the impact of the presence and size of pleural effusion on the LUSS-P/F ratio correlation, and subgroup analyses based on ARF etiology, the LUSS, hypoxemia severity, and respiratory rate.

Three different types of ultrasound machines were used for this study: Philips CX5 (Philips, Eindhoven, Netherlands), Philips Spark (Philips, Eindhoven, Netherlands), and Vivid T9 (GE Healthcare, Chicago, USA). Low-frequency curvilinear transducers were used, and B-lines were assessed at a minimum depth of 12 cm in accordance with current literature [13].

A LUSS was calculated based on the following process. First, the thorax was virtually divided into six zones bilaterally, as shown in Figure 1. The anterior and lateral zones were evaluated in the dorsal decubitus position, and the posterior zones in the contralateral decubitus position. For each zone, a score from 0 to 3 was determined (Table 3). The LUSS (0–36) was calculated by adding the scores for each of the 12 zones. Patients with a LUSS <2 were empirically considered to have no IS and were secondarily excluded from the study. Investigators also reported the presence of unilateral or bilateral pleural effusion. When present, pleural effusion size was evaluated on an end-expiration freeze-frame image, measuring the maximal distance between the parietal and visceral pleura in millimetres (Dmax). The LUSS was not communicated to the treating physician.

Figure 1. Thoracic zones used for lung ultrasound. AAL, anterior axillary line; PAL, posterior axillary line.
Table 3. Lung ultrasound definition and images illustrating the scores 0–3 used to calculate the lung ultrasound scores (LUSS). LUSS range from 0 to 36; they are calculated by adding together the scores given for each of the 12 thoracic zones.
ScoreDescriptionImage
0Normal aeration of the lung with the presence of A-lines, persistent pleural sliding, and less than three B-lines
1Interstitial syndrome, resulting in moderate loss of aeration with three or more B-lines spaced 7 mm apart
2Alveolar-interstitial syndrome, resulting in severe loss of aeration with coalescent B-lines spaced less than 3 mm apart
3Alveolar consolidation, leading to a complete loss of aeration with a tissue-like pattern on ultrasound

The four investigators (GN, AL, RC, PG) were blinded to any other procedures made for diagnostic purposes by the physician involved in the patient’s care. Investigators were trained in lung POCUS and evaluated themselves as confident in their ability to use it. This confidence was evaluated using a 5-point Likert scale (Table 4). All participating investigators strongly agreed with the statement that they were qualified to calculate a LUSS.  

Table 4. Likert scale used by operators to self-assess their ability to calculate the lung ultrasound score (LUSS).
ScoreResponse to statement “I am qualified to calculate a lung ultrasound score”
1Strongly disagree
2Disagree
3Undecided
4Agree
5Strongly agree

Patient identification data were collected using an electronic case report form through the RedCap software (REDCap Consortium, Vanderbilt University, Nashville, USA). Access was secured and restricted to the investigator, who could only view the data of patients that they included. The study coordinator (EV) was the sole individual with access to all data. These data were subsequently extracted from the software, anonymized, and stored in a secure computer file for analysis. 

Statistical analysis 

A sample of 78 patients was used to test a prespecified directional hypothesis that the ICU correlation would reach a target value of r = −0.70, using a one-sided α = 0.05 and 90% power. The correlation from the prior emergency department cohort (r = −0.486) informed the plausibility and choice of the target effect for planning purposes, but no formal between-cohort comparison was planned. Considering an attrition rate at 0.100, the sample size of this study was increased to 86 patients. 

Data analysis was performed using JMP Pro 16.0.0 software (SAS Institute, Cary, USA). Continuous variables were expressed as means with minimum and maximum values, standard deviations, and 95% confidence intervals. Discrete variables were reported as categories and expressed in numbers and percentages. Pearson’s correlation was used to measure the linear correlation between continuous variables. Comparisons between categorical variables were performed using the Chi-square test. Between-group comparisons of continuous variables were performed using the Wilcoxon–Mann–Whitney test. The significance threshold was set at a p-value of <0.05. Multiple linear regression was used to test the effect of continuous variables on the LUSS and the P/F ratio.  

Results

Patients and the availability of data

A flowchart showing patient screening and enrolment is provided in Figure 2. A total of 94 patients were initially included, although 8 were subsequently excluded: 7 due to the absence of delayed consent, and 1 due to the later discovery of chronic pulmonary fibrosis. Consequently, 86 patients were included in the final data analysis. The population characteristics of the patients included in the analysis are summarised in Table 5. Data for the primary endpoint were available for all included patients. Data at 24 and 48 hours were available for 71 and 44 patients, respectively.

Figure 2. Study flowchart. ARF: acute respiratory failure, ABG: arterial blood gas, COPD: chronic obstructive pulmonary disease, V-V or A-V ECMO: veno-venous or arterio-venous extracorporeal membrane oxygenation, LUS, lung ultrasound; LUSS, lung ultrasound score; Dmax: maximal distance between visceral and parietal pleura.
Table 5. Study population characteristics.
CharacteristicsNMean (SD) or Number (%)*
Age (years)N = 8665 (13.68)
SexN = 86
Male58 (67.44%)
Female28 (32.56%)
Weight (kg)N = 8679.47 (14.63)
ComorbiditiesN = 86
Pulmonary hypertension8 (9.3%)
Lung cancer4 (4.65%)
Chronic pleural effusion4 (4.65%)
History of heart failure21 (24.42%)
Chronic kidney failure7 (8.24%)
Dialysis2 (2.33%)
Cirrhosis2 (2.33%)
Acute respiratory failure etiology**N = 86
Bacterial pneumonia46 (54.76%)
Acute heart failure19 (22.62%)
Acute respiratory distress syndrome (ARDS)10 (12.05%)
Influenza pneumonia8 (9.52%)
Atelectasis5 (6.02%)
Extra-pulmonary restrictive syndrome3 (3.61%)
Covid-19 pneumonia1 (1.19%)
Immunotherapy-induced interstitial lung disease1 (1.19%)
Unknown2 (2.28%)
LUSS (0–36)N = 8614.55 (5.6)
P/F ratioN = 86161.44 (70.66)
SOFA Score (0–24)N = 865.73 (3.44)
Pleural effusionsN = 86
Unilateral14 (16.28%)
Bilateral24 (27.91%)
Dmax (mm)30.31 (17.42)
Arterial blood gas analysis (ABG)N = 86
pH7.43 (0.07)
Lactates (mmol/L)1.74 (1.85)
HCO3 (mmol/L)25.49 (3.94)
PaCO2 (mmHg)38.65 (8.2)
FiO2 (%)55 (23)
Vital signsN=86
Systolic blood pressure (mmHg)124.48 (26.97)
Heart rate (beat/min)90.57 (21.93)
Respiratory rate (breath/min)25.8 (9.25)
Temperature (Celsius °)36.86 (0.94)
Supplementary oxygenN=86
None1 (1.16%)
Nasal cannula24 (27.91%)
Simple oxygen mask3 (3.49%)
Non-rebreather mask1 (1.16%)
High-flow nasal cannula26 (30.23%)
Non-invasive ventilation10 (11.63%)
Invasive ventilation21 (24.42%)
LUSS at 24h (0-36)N = 7113.62 (6.42)
P/F ratio at 24h (mmHg)N = 71200.29 (87.27)
SOFA at 24h (0–24)N = 715.61 (3.91)
LUSS at 48h (0–36)N = 4413.87 (6.54)
P/F ratio at 48h (mmHg)N =44191.06 (87.13)
SOFA at 48h (0–24)N = 445.24 (4.17)
Ventilation-free days at 28 daysN =8621.76 (10.13)
Mortality at 28 daysN =8616 (18.6%)
* Continuous data are expressed as mean (SD) and discrete data as number (percentage).
** More than one etiology allowed.
LUSS, lung ultrasound score; Dmax, maximal distance between visceral and parietal pleura at the end of expiration; FiO2, fraction of inspired oxygen; PacO2, arterial partial pressure of carbon dioxide; PaO2, arterial partial pressure of oxygen; P/F ratio, arterial oxygen pressure-to-fraction of inspired oxygen ratio; SD, standard deviation; SOFA, sequential organ failure assessment.

Primary endpoint

A negative correlation of -0.2945 (95% CI: -0.4767 to -0.0881) was found between the LUSS and P/F ratio in the 86 patients admitted to the ICU with IS (Figure 3). Therefore, the study did not support the primary hypothesis that the ICU correlation would reach the prespecified target magnitude (r = −0.70).

Figure 3. Weak negative linear correlation between lung ultrasound score (LUSS) and arterial oxygen pressure-to-fraction of inspired oxygen (P/F) ratio.

Secondary endpoints

Negative correlations between the LUSS and P/F ratio were observed at 24 and 48 hours with a correlation coefficient of -0.1026 (95% CI: -0.3281 to 0.1339) and -0.095 (95% CI: -0.3842 to 0.2116), respectively. Correlations between LUSS and SOFA score were calculated, resulting in a positive correlation of 0.1537 (95% CI: -0.0601 to 0.3640) at admission, a positive correlation of 0.0700 (95% CI: -0.1677 to 0.3001) at 24 hours, and a negative correlation of -0.0088 (95% CI: -0.3015 to 0.2855) at 48 hours. Exploratory multivariable linear regression analyses, including adjustment for the SOFA score and presence and size of pleural effusion, did not materially modify the association between the LUSS and P/F ratio. In the largest subgroup of 46 patients with bacterial pneumonia, the correlation coefficient was -0.2759 (95% CI: -0.5656 to 0.0745). Other subgroup analyses revealed similar weak or negligible correlations between the LUSS and P/F ratio across different ARF etiologies, LUSS categories, hypoxemia severities, and respiratory rates.

Supplementary analysis

No statistically significant correlation between the LUSS and P/F ratio was observed in subgroups stratified according to the type of oxygen supplementation. The results are displayed in Table 6.  

Discussion

Primary outcome 

We found a linear negative correlation between the LUSS and P/F ratio among the patients admitted to the ICU with IS of any cause, although the coefficient of 0.2945 was considered weak [14]. This finding suggests the limited value of the LUSS when assessing the severity of IS in this specific population. Multiple concurrent mechanisms, including ventilator settings, hemodynamic and ventilation/perfusion mismatch may attenuate the relationship between ultrasound aeration patterns and oxygenation, which could partly explain the weak correlation observed in this ICU population. The failure to show a strong correlation may also be partly explained by the study settings. First, unlike the O2LUSS study, patients in the present study were admitted to the ICU, indicating a potentially higher disease severity. In support of this, the mean P/F ratio, mean FiO2, mean LUSS, the proportion of patients requiring invasive mechanical ventilation at admission, and 28-day mortality all suggest that the study cohort was critically ill. The mean SOFA score at admission was 5.73, corresponding to an estimated mortality risk of approximately 20% [15]. Furthermore, significant variability exists in the eligibility and inclusion criteria among studies reporting a stronger correlation between the LUSS and P/F ratio. A major distinction lies in the scope of patient populations studied: previous research often focused on a single type of IS, whereas the present study included patients with all types of IS [7,9,11]. Additionally, unlike most studies, the O2LUSS and O2LUSS-ICU studies excluded patients with chronic pathologies responsible for an ultrasonographic pattern of IS, as well as other conditions that, while not directly involving the lung interstitium, could nonetheless influence the LUSS or P/F ratio. For example, the presence of pulmonary hypertension in 9.3% of this study population, potentially impacting the P/F ratio independently of LUSS, may have influenced the correlation between the LUSS and P/F ratio. Finally, variability in LUSS calculation methods contributes to these discrepancies. Notably, some studies that identified stronger correlations did not employ the standardized twelve-zone lung ultrasound scoring system, further complicating direct comparisons between findings [16,17].

To our knowledge, besides the O2LUSS study, no other research has previously evaluated the correlation between the LUSS and P/F ratio regardless of IS type. As the O2LUSS study was conducted during the COVID-19 pandemic, 71% of the included patients had COVID-19 pneumonia. This predominance of a single etiology weakens the O2LUSS study conclusion that LUSS can be used as a tool to evaluate the severity of all types of IS. In the present study, the population was more representative of the post-pandemic ICU population—with bacterial pneumonia, acute heart failure, and ARDS being the three most common causes of IS. 

Secondary outcomes 

Correlation coefficients between LUSS and P/F ratio at 24 and 48 hours of inclusion were negligible or weak. Follow-up lung ultrasound at 24 and 48 hours was performed when feasible; however, follow-up organization was challenging, as investigators were not always available. This limited the ability to perform follow-up assessments and made repeated evaluations by the same operator almost impossible. Follow-up depended on investigator availability, patient presence in the ICU, and continued fulfilment of inclusion criteria. Any follow-up was discontinued when these conditions were no longer met. Reasons for missing assessments were not systematically recorded, which was a limitation that further restricts the generalizability of our conclusions regarding follow-up findings. Nevertheless, a substantial proportion of patients benefited from follow-up, with 83% evaluated at 24 hours and 51% at 48 hours. Some patients benefited from follow-up only at 24 or 48 hours. Two prior studies assessed the correlation between the LUSS and P/F ratio over time. Both studies examined small patient groups: one identified a negative linear correlation in 278 LUSSs conducted at random intervals in 33 COVID-19 patients, while the other showed the correlation at 72 and 92 hours after the implementation of extracorporeal membrane oxygenation in 22 patients with cardiogenic shock [11,18].

In contrast to earlier studies, this study did not find relevant correlation coefficients between LUSS and SOFA score at inclusion, nor at 24 or 48 hours, thus failing to support the hypothesis that LUSS could serve as a reliable indicator of severity. The use of the SOFA score as a severity marker in patients with IS, despite its original development to assess organ dysfunction in septic patients, may explain the absence of a stronger correlation.

The correlation coefficient was also weak between the LUSS and P/F ratio in the large subgroup of 46 patients suffering from bacterial pneumonia. To our knowledge, this correlation has not been previously assessed in a population of patients with bacterial pneumonia. Bacterial pneumonia is generally responsible for focal lesions, while the LUSS is a global score exploring the whole lung parenchyma, which may explain the weakness of the correlation. Contrary to several previous studies, this study also failed to show relevant correlations in subgroups of 19 acute heart failure patients and 10 ARDS patients [9–11]. The small number of patients in these subgroups may explain the absence of any correlation. These ARF etiology-subgroup analyses should be considered exploratory and interpreted with caution, as the etiology was determined from medical records by the treating ICU team without independent adjudication. Categories were not mutually exclusive, and some overlap between groups was unavoidable.

Supplementary analysis

No statistically significant correlation between the LUSS and P/F ratio was observed in subgroups stratified according to the type of oxygen supplementation. A moderate correlation in the invasive ventilation subgroup (r = −0.426, p = 0.054, N = 21) represents the strongest and closest to significant association observed across all subgroups. This finding is clinically relevant, as FiO2 is precisely measured in mechanically ventilated patients, supporting the hypothesis that measurement error in FiO2 may attenuate the overall correlation. These analyses were exploratory, and several subgroups included a limited number of patients. Therefore, these findings should be interpreted with caution, and further research involving larger patient cohorts is warranted.

Strengths and limitations

The ultrasound probe, timing of lung POCUS, and operator’s level of expertise may affect the assessment of B-lines [20]. In the present multicentre study, three different ultrasound machines were used, although only low-frequency curvilinear transducers were permitted when performing lung POCUS to minimize the variability in the B-line evaluation. The four investigators involved were all certified ICU specialists using clinical ultrasound in their daily practice. They all regarded themselves as confident in LUSS, with a self-evaluated score of 5 on a 5-point Likert scale. As LUSS images were neither recorded nor reviewed, inter-rater reliability could not be assessed, and no external validation was possible. Although four operators participated, most examinations were performed by a single operator. This may reduce interoperator variability as a source of heterogeneity but also limits the feasibility of formally estimating operator effects using multilevel models. Additionally, in patients receiving supplemental oxygen via nasal cannula, simple mask, or non-rebreathing mask, the amount of FiO2 delivered could only be estimated as it depends on multiple factors. This non-differential measurement variability would be expected to attenuate correlations toward the null. Additionally, the exclusion of patients with a LUSS <2, considered as having no IS, may have restricted the range of the predictor variable and mechanically attenuated the correlation coefficient, potentially leading to an underestimation of the true association between the LUSS and P/F ratio. Although a maximum interval of ten minutes was defined between lung POCUS and arterial blood gas sampling to reduce variability in the patient’s clinical status, this approach does not fully eliminate the risk of temporal bias. Indeed, even short-term physiological fluctuations, particularly in unstable patients, may have occurred during this interval, potentially contributing to the weak correlation observed. The time from symptom or disease onset to ICU admission was heterogeneous and not systematically recorded, potentially contributing to clinical heterogeneity and affecting the observed correlations. The distribution of patients between centres could be another limitation of the present study, since 85% were included from one of the secondary hospitals. Moreover, the patient population in the hospital is known to be socioeconomically disadvantaged with limited healthcare access. Therefore, it could be assumed that many of the patients included in the present study may present undiagnosed chronic pathologies responsible for chronic IS that impact the P/F ratio. 

Conclusions

The correlation between the LUSS and P/F ratio has been widely studied in COVID-19 patients, confirming that LUSS is a reliable severity indicator for this population. This finding caused significant enthusiasm for its use in other types of IS in the ICU. In the present post-pandemic study, the weak or negligible correlation coefficients between the LUSS and P/F ratio or SOFA score suggest that the LUSS may not be sufficiently reliable when used alone as a severity marker of IS. Overall, the study does not support the use of LUSS as a severity marker for patient follow-up, although further investigation is warranted in settings where follow-up can be performed for all patients to fully evaluate its utility and minimize selection bias. The potential of combining LUSS with other severity indicators, and of standardizing its assessment through automated calculation methods, should be explored to improve both its reliability and clinical applicability.

Acknowledgements

Collaborators: Céline Bugli PhD (statistical support); Lara Absil (research support); Victoria Grace (manuscript review).

Ethics Statement

Before the start of patient inclusion, the study protocol was approved by the principal institutional review board: Comité d’éthique Hospitalo-Facultaire Saint Luc-UCL (No: 2022/24NOV/444). Secondarily, the protocol was approved by the institutional review boards of the two other participating hospitals. This study was registered on clinicaltrials.gov (NCT05631756). The publication follows the STROBE statement guidelines

Disclosure Statement

None of the authors of this work have any conflicts of interest, competing statements, financial disclosures or funding to declare.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author Contributions

EV: conceptualization, methodology, project administration, validation, formal analysis, supervision, writing – original draft, writing – review & editing. FD: conceptualization, methodology, formal analysis, supervision, writing – review and editing. CP: data curation, writing – review and editing. ZP: data curation, writing – review and editing. AL: investigation, writing – review and editing. RC: investigation, writing – review and editing. MV: supervision, writing – review and editing. JBM: supervision, writing – review and editing. GN: investigation, writing – review and editing. PG: conceptualization, methodology, investigation, supervision, writing – review and editing.

References

1. Volpicelli G, Elbarbary M, Blaivas M, Lichtenstein DA, Mathis G, Kirkpatrick AW, Melniker L, Gargani L, Noble VE, Via G, Dean A, Tsung JW, Soldati G, Copetti R, Bouhemad B, Reissig A, Agricola E, Rouby JJ, Arbelot C, Liteplo A, Sargsyan A, Silva F, Hoppmann R, Breitkreutz R, Seibel A, Neri L, Storti E, Petrovic T; International Liaison Committee on Lung Ultrasound (ILC-LUS) for International Consensus Conference on Lung Ultrasound (ICC-LUS). International evidence-based recommendations for point-of-care lung ultrasound. Intensive Care Med. 2012;38(4):577-591.

2. Mojoli F, Bouhemad B, Mongodi S, Lichtenstein D. Lung ultrasound for critically ill patients. Am J Respir Crit Care Med. 2019;199(6):701-714.

3. Volpicelli G, Mussa A, Garofalo G, Cardinale L, Casoli G, Perotto F, Fava C, Frascisco M. Bedside lung ultrasound in the assessment of alveolar-interstitial syndrome. Am J Emerg Med. 2006;24(6):689-696.

4. Bilici D, Doğan C, Aşik M, Menek G, Kazci ZN. Thoracic ultrasonography in chronic obstructive pulmonary disease: A and B lines. Am J Med Sci. 2026;371(5):419-425. doi: 10.1016/j.amjms.2026.01.007

5. Via G, Lichtenstein D, Mojoli F, Rodi G, Neri L, Storti E, Klersy C, Iotti G, Braschi A. Whole lung lavage: a unique model for ultrasound assessment of lung aeration changes. Intensive Care Med. 2010;36(6):999-1007.

6. Wang D, Qi Y. Lung ultrasound score and in-hospital mortality of adults with acute respiratory distress syndrome: a meta-analysis. BMC Pulm Med. 2024;24(1):62.

7. Lai SY, Schafer JM, Meinke M, Beals T, Doff M, Grossestreuer A, Hoffmann B. Lung Ultrasound Score in COVID-19 Patients Correlates with PO2/FiO2, Intubation Rates, and Mortality. West J Emerg Med. 2024;25(1):28-39.

8. Fan E, Brodie D, Slutsky AS. Acute respiratory distress syndrome. JAMA. 2018;319(7):698-710.

9. Zhao Z, Jiang L, Xi X, Jiang Q, Zhu B, Wang M, Xing J, Zhang D. Prognostic value of extravascular lung water assessed with lung ultrasound score by chest sonography in patients with acute respiratory distress syndrome. BMC Pulm Med. 2015;15:98.

10. Todur P, Chaudhuri S, Amara V, Srikant N, Prakash P. Correlation of oxygenation and radiographic assessment of lung edema (RALE) score to lung ultrasound score (LUS) in acute respiratory distress syndrome (ARDS) patients in the intensive care unit. Can J Respir Ther. 2021;57:53-59.

11. Wang R, Zhou M, Man Y, Zhu Y, Ding W, Liu Q, Sun B, Yan L, Zhang Y, Zhou H, Wang L. Lung ultrasound to evaluate pulmonary changes in patients with cardiogenic shock undergoing extracorporeal membrane oxygenation: a retrospective study. BMC Anesthesiol. 2023;23(1):181.

12. Vasseur E, Moureau G, Fasseaux A, Peyskens L, Gendebien F, Thys F, Dupriez F. Correlation between hypoxaemia and lung ultrasound score in patients presenting to an emergency department with interstitial syndrome: a prospective physiological study. Crit Care Resusc. 2023;24(3):233-241.

13. Duggan NM, Goldsmith AJ, Saud AAA, Ma IWY, Shokoohi H, Liteplo AS. Optimizing Lung Ultrasound: The Effect of Depth, Gain and Focal Position on Sonographic B-Lines. Ultrasound Med Biol. 2022;48(8):1509-1517.

Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth Analg. 2018;126(5):1763-1768.

14. Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001;286(14):1754-1758.

15. Rojatti M, Regli IB, Zanforlin A, Ferretti E, Falk M, Strapazzon G, Gamper M, Zanon P, Bock M, Rauch S. Lung ultrasound and respiratory pathophysiology in mechanically ventilated COVID-19 patients-an observational trial. SN Compr Clin Med. 2020;2(11):1970-1977.

16. Perrone T, Soldati G, Padovini L, Fiengo A, Lettieri G, Sabatini U, Gori G, Lepore F, Garolfi M, Palumbo I, Inchingolo R, Smargiassi A, Demi L, Mossolani EE, Tursi F, Klersy C, Di Sabatino A. A new lung ultrasound protocol able to predict worsening in patients affected by severe acute respiratory syndrome coronavirus 2 pneumonia. J Ultrasound Med. 2021;40(8):1627-1635.

17. Dargent A, Chatelain E, Si-Mohamed S, Simon M, Baudry T, Kreitmann L, Quenot JP, Cour M, Argaud L; COVIDLUS Study Group. Lung ultrasound score as a tool to monitor disease progression and detect ventilator-associated pneumonia during COVID-19-associated ARDS. Heart Lung. 2021;50(5):700-705.

18. Li L, Qin A, Yang X, Zhou S, Luo Y, Zhu F, Hu B, Li J, Cai S, Peng Z. Findings and prognostic value of lung ultrasonography in Coronal Virus Disease 2019 (COVID-19) pneumonia. Shock. 2021;56(2):200-205.

19. Pivetta E, Baldassa F, Masellis S, Bovaro F, Lupia E, Maule MM, Tizzani M, Porrino G, Ferreri E, Volpicelli G. Sources of variability in the detection of B-lines using lung ultrasound. Ultrasound Med Biol. 2018;44(6):1212-1216.

Posted in .

Leave a Reply

Your email address will not be published. Required fields are marked *